Anti-PSMA Immunocytokine, IgG (2C9)-IL2 (ACFP-SH007)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-PSMA IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the PSMA as well as the biological activity of IL2. This antibody-cytokine fusion protein is an C-terminus interleukin-2 (IL2)-fused immunocytokine, exhibited enhanced cytotoxic activity against PSMA-expressing prostate cancer cells in the presence of PBMCs. It has a therapeutic potential for prostate cancer by stimulating lymphocyte-mediated antitumor cytotoxicity. This immunocytokine was designed for treating prostate cancer.
Specifications
- Target
- PSMA
- Molecule Class
- IgG1-IL2
- Species Reactivity
- Human
- Host
- Chimeric (Mouse-Human)
- Expression Host
- CHO
- Clone
- 2C9
- Related Disease
- prostate cancer
- Cytokines 1
- IL2
- Cytokines 1 Description
- Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- FOLH1; folate hydrolase (prostate-specific membrane antigen) 1; PSM; FGCP; FOLH; GCP2; PSMA; mGCP
- Entrez Gene ID
- 2346
- UniProt ID
- Q04609
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: